Cargando…
The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
Vedolizumab is a humanized monoclonal α4β7 integrin antibody used in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Limited data are available on the use of vedolizumab in patients with concurrent cirrhosis and inflammatory bowel disease (IBD). Patients with cirrhosis are unique, as...
Autores principales: | Kapila, Nikhil, Flocco, Gianina, Shen, Bo, Modaresi Esfeh, Jamak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168050/ https://www.ncbi.nlm.nih.gov/pubmed/30305988 http://dx.doi.org/10.7759/cureus.3080 |
Ejemplares similares
-
Safety of anti-TNF agents in patients with compensated cirrhosis: a case-control study
por: Kapila, Nikhil, et al.
Publicado: (2021) -
Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab
por: Haider, Mahnur, et al.
Publicado: (2020) -
Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy
por: Meeralam, Yaser, et al.
Publicado: (2023) -
Steatosis and hepatitis C
por: Modaresi Esfeh, Jamak, et al.
Publicado: (2016) -
Unusual MRI appearance of a well differentiated hepatocellular carcinoma, mimicking a cavernous hemangioma: A case report
por: Ansari-Gilani, Kianoush, et al.
Publicado: (2019)